Basic-Jukic Nikolina, Kes Petar, Bubic-Filipi Ljubica, Brunetta Bruna
Department of Dialysis, University Hospital Centre Zagreb, Zagreb, Croatia.
Hematology. 2007 Feb;12(1):63-7. doi: 10.1080/10245330600938687.
Thrombotic microangiopathy (TMA) is a syndrome characterized by thrombocytopenia, microangiopathic hemolytic anemia, neurologic abnormalities, fever and renal dysfunction. This retrospective analysis sought to determine the clinical characteristics and outcome of patients with TMA treated with plasma exchange at the Department of Dialysis, University Hospital Zagreb. From 1982 to July 2005, 17 patients (10 male and 7 female, age ranging from 18 to 74 years) have been diagnosed with TMA. The most common presenting symptom was purpura in 76.5%, followed by neurologic disturbance in 70.5%, renal function abnormality in 41.1%, and fever in 29.4% of patients. Patients were treated with a daily plasma exchange, which was continued until the normalization of platelet count with minimal hemolysis. Plasma exchange treatment was first tapered and later discontinued with careful monitoring of laboratory parameters. Of the 17 patients, 13 achieved complete remission after 5-32 sessions, two had partial response, and two had no response and died of progressive disease. Four patients developed chronic relapsing TMA, and three of them progressed to end-stage renal disease. Survival at 1 year in our series exceeds 88%, but decreased with duration of follow-up. Overall, with the median follow up of 5 years, 6 patients died from consequences of TMA (35.3%); three with chronic TMA, and 2 in the acute phase of progressive disease. A 74-year old male who developed TMA after prostate cancer died from disseminated malignant disease. Our results demonstrate a high incidence of renal function abnormalities in patients with TMA at presentation, but also during long term follow-up. Development of end-stage renal disease was associated with poor prognosis. Further studies, long term follow-up and establishment of international registries are needed to clarify many dilemmas associated with the diagnosis, treatment and outcomes of patients with TMA.
血栓性微血管病(TMA)是一种以血小板减少、微血管病性溶血性贫血、神经功能异常、发热和肾功能不全为特征的综合征。这项回顾性分析旨在确定在萨格勒布大学医院透析科接受血浆置换治疗的TMA患者的临床特征和预后。从1982年至2005年7月,17例患者(10例男性,7例女性,年龄在18至74岁之间)被诊断为TMA。最常见的首发症状是紫癜,占76.5%,其次是神经功能障碍,占70.5%,肾功能异常占41.1%,发热占29.4%。患者接受每日血浆置换治疗,持续进行直至血小板计数恢复正常且溶血程度降至最低。血浆置换治疗首先逐渐减量,随后在仔细监测实验室指标的情况下停药。17例患者中,13例在接受5至32次治疗后完全缓解,2例部分缓解,2例无反应并死于疾病进展。4例患者发生慢性复发性TMA,其中3例进展为终末期肾病。我们系列研究中1年生存率超过88%,但随随访时间延长而下降。总体而言,中位随访时间为5年,6例患者死于TMA的并发症(35.3%);3例为慢性TMA,2例死于疾病进展的急性期。一名74岁男性在患前列腺癌后发生TMA,死于播散性恶性疾病。我们的结果表明,TMA患者在就诊时以及长期随访期间肾功能异常的发生率都很高。终末期肾病的发生与预后不良相关。需要进一步研究、长期随访并建立国际登记系统,以阐明与TMA患者的诊断、治疗和预后相关的许多难题。